＜この研究が熱い！気になる論文紹介＞ 中等症〜重症乾癬を対象とした、世界初の経口IL-23受容体阻害薬「イコトロキンラ」の第Ⅲ相試験結果を読み解く

Gold LS, Armstrong AW, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406:1363-74. doi: 10.1016/S0140-6736(25)01576-4.